PureTech Health plc (NASDAQ:PRTC - Get Free Report)'s share price hit a new 52-week high on Thursday . The stock traded as high as $34.00 and last traded at $31.96, with a volume of 14162 shares trading hands. The stock had previously closed at $27.95.
PureTech Health Stock Up 3.3 %
The company has a fifty day moving average price of $25.81 and a two-hundred day moving average price of $23.43.
Institutional Investors Weigh In On PureTech Health
A hedge fund recently raised its stake in PureTech Health stock. Jane Street Group LLC grew its stake in shares of PureTech Health plc (NASDAQ:PRTC - Free Report) by 15.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,632 shares of the company's stock after purchasing an additional 1,289 shares during the period. Jane Street Group LLC's holdings in PureTech Health were worth $263,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.04% of the company's stock.
About PureTech Health
(
Get Free Report)
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies.
Featured Articles
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
